

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Open Session

Date: 8/5/2026

Present: Peter Halfmann, Matt Reynolds, Dennis Halterman, Donna Neumann, Yevgenya Grinblat, Warren Rose, Amita Kapoor, Stephanie Kutz, Andy Attwood, Ryan Stoffel, Marta Gaglia, Garret Suen, Joel Malak, Ryan Behrens, Sabine Pellett

Consultants: Tony Mcgrath, Lissa Koop, Darren Berger, Christina Pier, Heather Mc Fadden, Carrie Ensrud, Jennifer Wang

OBS: Tony Mcgrath, Karen Demick, Christina Pier, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Kathy Krasny

Guests: Sarah Johnson, CALS

Call to order: The meeting was called to order by Garret Suen, at Zoom at 1:31pm

Announcements: The IBC meeting is open to the public.

Review of Minutes: A motion to approve the open session minutes of the following IBC meetings was Unanimously adopted.

Institutional Biosafety Committee meeting on (7/1/2026)

Institutional Biosafety Committee meeting on (7/15/2026)

07/01/2026 minutes: Warren Rose, absent Yevgenya Grinblat, absent Joel Malak, absent Peter Halfmann, abstain Marta Gaglia, abstain Amita Kapoor, abstain 07/15/2026 minutes: Warren Rose, absent Yevgenya Grinblat, absent Joel Malak, absent Marta Gaglia, abstain Amita Kapoor, abstain Donna Neumann, abstain

Approval of Registered Protocols: A motion to approve registered protocols was Unanimously adopted

Warren Rose, absent Joel Malak, absent

Other business - open session

- **Agenda Items - Documents For Open Session:**
- **List of Registered Protocols_060326-070126_AM.xlsx**
- **List of Registered Protocols_060326-070126_GP.xlsx**

Review of research protocols - open session

 **B00001245**

 **B00001260**

 **B00001270**

 **B00001277**

 **B00001281**

 **B00001285**

Review of research amendments - open session

 **B00000018-AM024**

 **B00000095-AM026**

 **B00000195-AM016**

 **B00000254-AM007**

 **B00000267-AM013**

 **B00000415-AM010**

 **B00000454-AM022**

 **B00000543-AM011**

 **B00000553-AM007**

 **B00000764-AM010**

 **B00000813-AM006**

Announcements

null

The meeting adjourned 4:00pm

- **Bio Protocol Number: B00001245**
PI Name: Anne Letocha

Protocol Title: School of Nursing Core Freezer Storage

Motion: IBC approved protocol

Motion Made By: Stephanie Kutz

Motion Seconded By: Marta Gaglia

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Warren Rose, absent Joel Malak, absent

Biosafety Level: Not applicable (non-laboratory area);

Containment Equipment: Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: null

NIH Guidelines:

Summary of IBC Review: This is a new protocol. The School of Nursing proposes to provide researchers with long term freezer storage for human biospecimens.

Biosafety is adequately addressed.

- **Bio Protocol Number: B00001260**

PI Name: Jonathan Stefely

Protocol Title: Comparative metabolism and biochemistry of amoeba

Motion: IBC approved with contingencies

Motion Made By: Yevgenya Grinblat

Motion Seconded By: Dennis Halterman

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent Sabine Pellett, abstain

Biosafety Level: BSL2; BSL2; BSL1; BSL2; BSL2; BSL1;

Containment Equipment: Biological safety cabinet (BSC); Other - Autoclave unit; Not applicable; Other - Biosafe centrifugation equipment.; Chemical fume hood, Other - Biosafe centrifugation equipment.; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-1-a) (III-D-1-b); (III-F-8); (III-F-1);

Summary of IBC Review: This is a new protocol. This lab proposes to study the biology and biochemistry of pathogenic amoeba, acanthamoeba. The IBC discussed the proposed changes and contingencies related to visitors.

- **Bio Protocol Number: B00001270**

PI Name: [REDACTED]

Protocol Title: [REDACTED] lab BSL3 protocol

Motion: IBC approved with contingencies

Motion Made By: Donna Neumann

Motion Seconded By: Ryan Behrens

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Matt Reynolds, abstain Peter Halfmann, abstain Joel Malak, absent

Biosafety Level: BSL3; BSL3; BSL3; BSL3; BSL3;

Containment Equipment: Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-7); (III-E-1); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This is a new biosafety protocol for this lab at the new Elements Building. This lab operates Virology Services by producing and titrating MPox viral stocks at BSL3 to be used by other researchers in nonhuman primate research. The IBC discussed the proposed changes and had no additional concerns once the contingencies are addressed.

- **Bio Protocol Number: B00001277**

PI Name: [REDACTED]

Protocol Title: Interaction of macrophages with Staphylococcus aureus

Motion: IBC approved with contingencies (protocol must go back to IBC reviewers)

Motion Made By: Warren Rose

Motion Seconded By: Dennis Halterman

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent

Biosafety Level: BSL2; BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL2; BSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Chemical fume hood; Not applicable; Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Other - centrifuges, microscopes; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required

institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a)(III-D-1-b); (III-E); (III-E-1); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: This is a new protocol. This lab proposes to study new antibacterial effectors in immune cells that target the pathogen *Staphylococcus aureus* and define how bacteria adapt to stress imposed by the host. IBC discussed clarification of vectors, aerosol containment procedures, and PPE practices.

- **Bio Protocol Number: B00001281**

PI Name: Sarah Loerch

Protocol Title: Localized translational control in pain

Motion: IBC approved with contingencies

Motion Made By: Stephanie Kutz

Motion Seconded By: Marta Gaglia

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Warren Rose, absent Joel Malak, absent

Biosafety Level: BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from

the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-E); (III-F-8);

Summary of IBC Review: This is a new protocol. This lab proposes to study how ribosomes are controlled by signals and how different stimuli change regulation.

Research utilizes non-pathogenic microbes, and cell lines to further research aims.

Clarification of spill and release procedures is needed.

- **Bio Protocol Number: B00001285**

PI Name: [REDACTED]

Protocol Title: Human cell culture, human biospecimens and murine models for study of the immune system

Motion: IBC tabled the protocol

Motion Made By:

Motion Seconded By:

Committee Action: Other

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL2; BSL2; BSL2; ABSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; BSL1; BSL2; BSL1; ABSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood, Other - bioBubble; Chemical fume hood; Other - This is a vivarium procedure room and will be used for irradiation of mice only ; Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable;

Committee Review: There was insufficient information for risk assessment. The protocol was tabled.

Facilities: null

Required Institutional Training: null

Lab-specific Training and Expertise: null

PPE, Controls, and Practices: null

NIH Guidelines Requirements: null

Administrative: null

NIH Guidelines: (III-D-4-b); (III-F-8);

Summary of IBC Review: This is a new protocol. This lab proposes to study autoimmune disease and site-specific immunity in mucosal and exocrine tissues, focusing on graft-versus-host disease (GVHD) in recipients of non-self (allogeneic)

blood cell transplants. The IBC tabled the protocol due to insufficient information to perform a risk assessment.

- **Bio Protocol Number: B00000018-AM024**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 024 for Studies of the influenza virus polymerase

Motion: IBC approved protocol

Motion Made By: Peter Halfmann

Motion Seconded By: Matt Reynolds

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent Marta Gaglia, absent

Biosafety Level: BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Not applicable; Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-7); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-1); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This lab studies the emergence of drug resistance in a

traceable infection model. This amendment proposes to add use of a different anti-viral compound and cell line. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000095-AM026**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 026 for Stem Cell Therapies in Hematology and Infectious Diseases

Motion: IBC tabled the protocol

Motion Made By:

Motion Seconded By:

Committee Action: Other

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL2, BSL2, Other - ABSL2+/BSL2+; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; Not applicable (non-laboratory area); BSL2; ABSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; ABSL2; ABSL2; ABSL2; BSL2; ABSL2; BSL2; ABSL2; ABSL2; BSL2; BSL2; ABSL2; ABSL2; BSL2; BSL2; Not applicable (non-laboratory area); ABSL2; ABSL2; ABSL2; ABSL2; BSL2; ABSL2; ABSL2, Other - ABSL2+; BSL2; BSL2; BSL2; ABSL2, BSL2, Other - ABSL2+/BSL2+; ABSL2, BSL2; Not applicable (non-laboratory area); BSL2;

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Other - Vented cabinet and backdraft table; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood, Other - down draft table for tissue trimming; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC); Other - No aerosol generation. Non-fixed samples are never opened and contained in original container (e.g. 6-well plate, 10cm dish); Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Other - Other - No aerosol generation. Non-fixed samples are never opened and contained in original container (e.g. 6-well plate, 10cm dish); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Other - -20 degree celcius freezer; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Other - Robots will do isolations of DNA/RNA from samples like Maxwell, MaxPrep, and KingFisher;

Committee Review: There was insufficient information for risk assessment. The

protocol was tabled.

Facilities: null

Required Institutional Training: null

Lab-specific Training and Expertise: null

PPE, Controls, and Practices: null

NIH Guidelines Requirements: null

Administrative: null

NIH Guidelines: (III-D-4-b); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This lab's research aims to advance the clinical use of stem cells through development of novel sources. This amendment proposes to add SIV/SHIV studies in mice. The IBC tabled the protocol due to insufficient information to perform a risk assessment.

- **Bio Protocol Number: B00000195-AM016**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 016 for Mechanotransduction and the Regulation of Skeletal Muscle Mass

Motion: IBC approved with contingencies

Motion Made By: Peter Halfmann

Motion Seconded By: Donna Neumann

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent

Biosafety Level: BSL1; BSL2; ABSL2; ABSL1, BSL1; BSL1; BSL1; BSL1; BSL2; BSL2; BSL1; BSL2; ABSL2, BSL2; ABSL1;

Containment Equipment: Not applicable; Biological safety cabinet (BSC); Other - Contains an autoclave for the disinfection of animal bedding and cages ; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Other - Contains an autoclave for the disinfection of biohazardous materials; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved

in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-3); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies muscle mass loss, including ways to prevent loss of muscle mass due to immobilization and aging. This amendment proposes that AAV administration will take place outside of containment with the additional use of respiratory protection. Biosafety is adequately addressed and minor administrative contingencies were discussed.

- **Bio Protocol Number: B00000254-AM007**

PI Name: Joshua Lang

Protocol Title: Amendment/Renewal 007 for Epigenetic Targeting Therapies and Biomarkers in Prostate Cancer

Motion: IBC approved protocol

Motion Made By: Yevgenya Grinblat

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Other - Autoclave located in hallway.; Not applicable; Not applicable;

Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC); Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved

in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-E-1); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies epigenetic targeting and biomarkers for prostate cancer. This amendment proposes the addition of new commercial cell lines to the established protocol. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000267-AM013**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 013 for Pathogenesis, immunology and drug discovery related to fungal infections by *Blastomyces dermatitidis* and other fungi.

Motion: IBC approved with contingencies

Motion Made By: Warren Rose

Motion Seconded By: Sabine Pellett

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent

Biosafety Level: ABSL2; BSL2; ABSL3; ABSL3; ABSL2; BSL3; Other - Anteroom; BSL2; BSL2; BSL2; Other - BSL3 anteroom; ABSL2; Not applicable (non-laboratory area); BSL2; ABSL1; Not applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-D-2-a); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: This lab studies pathogenesis, immunology and drug discovery related to fungal infections. This amendment proposes the addition of projects with *Galleria mellonella* (wax moth larvae) and changes in lipopolysaccharide (LPS) stock concentrations. The IBC discussed the proposed changes and had no additional concerns once the contingencies are addressed.

- **Bio Protocol Number: B00000415-AM010**

PI Name: Silvia Cavagnero

Protocol Title: Amendment/Renewal 010 for Mechanisms of Protein Folding in Vitro and in the Cell

Motion: IBC approved protocol

Motion Made By: Stephanie Kutz

Motion Seconded By: Marta Gaglia

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Warren Rose, absent Joel Malak, absent

Biosafety Level: BSL2; BSL1; BSL1; BSL1; BSL2; BSL1; BSL1; BSL1; BSL1; BSL1; BSL1; BSL2; BSL2; BSL1; BSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Not applicable; Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Chemical fume hood; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-E); (III-F-8);

Summary of IBC Review: This lab studies the mechanisms of protein folding in vitro and in cells. In this amendment the addition of work with protein synthesis kits. The spill protocol and emergency response procedures have been updated. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000454-AM022**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 022 for The role of nutrient-sensing kinases signaling in diabetes, metabolism and aging

Motion: IBC rejected protocol

Motion Made By: Matt Reynolds

Motion Seconded By: Peter Halfmann

Committee Action: Other

Nay Votes, Abstentions, Absentees: Joel Malak, absent

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL1; BSL1; BSL1; ABSL1; BSL2; BSL2; BSL1; BSL1; ABSL2; BSL1; BSL2; BSL2; BSL1; ABSL2; ABSL1; ABSL1; BSL2;

Containment Equipment: Not applicable; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Proposed work may not take place.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This lab studies how dietary and pharmaceutical interventions can be used to promote healthy aging and extend lifespan. This amendment proposes to change disinfectant products used. The IBC discussed appropriate disinfection practices for the laboratory's work. The IBC rejected the protocol.

- **Bio Protocol Number: B00000543-AM011**

PI Name: Jiaoyang Jiang

Protocol Title: Amendment/Renewal 011 for Investigation of protein post-translational modifications in biology and disease models

Motion: IBC approved with contingencies

Motion Made By: Yevgenya Grinblat

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent

Biosafety Level: BSL1; BSL1; BSL2; BSL1; BSL2; BSL1; BSL1; BSL2; BSL1; BSL2; BSL1; BSL2; BSL1; BSL1; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Chemical fume hood; Not applicable - Autoclave; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies protein post-translational modifications in biology and disease models. This amendment proposes to add mouse cell and tissue work with a collaborator. Minor administrative edits are needed otherwise biosafety is adequately addressed.

- **Bio Protocol Number: B00000553-AM007**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 007 for MAMMALIAN LACTATION PHYSIOLOGY

Motion: IBC approved with contingencies

Motion Made By: Sabine Pellett

Motion Seconded By: Amita Kapoor

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent Warren Rose, absent Yevgenya Grinblat, absent

Biosafety Level: BSL2; Not applicable (non-laboratory area); BSL2; Not applicable (non-laboratory area); Not applicable (non-laboratory area); BSL2; BSL1; ABSL1; BSL1; BSL1; Not applicable (non-laboratory area);

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Ventilated HEPA-filtered housing or rack system; Chemical fume hood; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-F-8); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies the influence of serotonin and SSRIs on mammary cell regulation, bone density, milk production, and reproduction. The lab uses animal models, including cattle. The amendment covers administration of LPS to cattle. Proposed biosafety levels are BLS2 and ABSL1. The IBC discussed BSL2 practices and containment, risk assessment, respiratory protection, LPS handling procedures, spill protocol attachments, and PPE practices.

- **Bio Protocol Number: B00000764-AM010**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 010 for Analysis of immunology, virology and pathogenesis of virus infections

Motion: IBC approved with contingencies

Motion Made By: Ryan Behrens

Motion Seconded By: Matt Reynolds

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent Warren Rose, absent Yevgenya Grinblat, absent

Biosafety Level: BSL2, Other - This is a BSL2+ Lab; BSL2; ABSL2; ABSL2; ABSL2 - ABSL2 with enhanced practices; BSL2; ABSL2; BSL2; BSL2; BSL2; ABSL2 - ABSL2- Biosafety level 3 practices in ABL2 area; ABSL2; ABSL2; ABSL2; BSL2; BSL2; BSL2; Not applicable (non-laboratory area); ABSL2; BSL2; BSL2; BSL2; ABSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; ABSL2; BSL2; BSL2; ABSL2; ABSL2 - ABSL2+ enhanced biosafety level 2 procedures to protect against exposure to highly infectious agents; ABSL2; Other - BSL2+; BSL2, Other - BSL2+;

Containment Equipment: Biological safety cabinet (BSC), Other - Robots will do isolations of DNA/RNA from samples. System is a self-contained Maxwell; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet

(BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-1-a) (III-D-1-b); (III-F-8);

Summary of IBC Review: This lab studies pathogenesis of infections during pregnancy and infancy, examining nonhuman primate body fluids and tissues for their immune responses to assess the spread of viruses and bacteria in tissues during pregnancy. This amendment proposes alternate procedures for storage of Mpox samples and updates to the BSL2 with BSL3 practices manual. The IBC discussed lab member training, spill & release procedures, exposure response, signage and access control during active Mpox work.

- **Bio Protocol Number: B00000813-AM006**

PI Name: Nathaniel Sharp

Protocol Title: Amendment/Renewal 006 for Evolutionary genetics of mutation

Motion: IBC approved with contingencies

Motion Made By: Dennis Halterman

Motion Seconded By: Sabine Pellett

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Joel Malak, absent Warren Rose, absent Yevgenya Grinblat, absent Donna Neumann, absent

Biosafety Level: BSL1; BSL1; BSL1; BSL1; BSL2; BSL2; BSL1; BSL2; BSL1; BSL2; BSL1; BSL1; BSL1; BSL2; BSL2;

Containment Equipment: Not applicable; Chemical fume hood; Not applicable; Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: null

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-a) (III-D-4-b); (III-D-1-a) (III-D-1-b); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies the evolutionary genetics of mutation using fruit flies and yeast to identify where genetic variation arises spontaneously. This amendment proposes addition of recombinant *C. albicans* and waxmoth worm larvae to the protocol. The IBC reviewed the protocol and added contingencies related to practices and administrative items.

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Closed Session

Date: 8/5/2026

Present: Peter Halfmann, Matt Reynolds, Dennis Halterman, Donna Neumann, Yevgenya Grinblat, Warren Rose, Amita Kapoor, Stephanie Kutz, Andy Attwood, Ryan Stoffel, Marta Gaglia, Garret Suen, Joel Malak, Ryan Behrens, Sabine Pellett

Consultants: Tony Mcgrath, Lissa Koop, Darren Berger, Christina Pier, Heather Mc Fadden, Carrie Ensrud, Jennifer Wang

OBS: Tony Mcgrath, Karen Demick, Christina Pier, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Kathy Krasny

Guests: Sarah Johnson, CALS

Call to order: The meeting was called to order by Garret Suen, at Zoom at 1:31pm

Announcements: The IBC meeting is closed to the public.

Review of Minutes: A motion to approve the closed session minutes of the following IBC meetings was Unanimously adopted.

Institutional Biosafety Committee meeting on (7/1/2026)

Institutional Biosafety Committee meeting on (7/15/2026)

Warren Rose, absent Marta Gaglia, abstain Amita Kapoor, abstain Donna Neumann, abstain Peter Halfmann, abstain

Other business - closed session

- **Agenda Items - Documents For Closed Session:**

Review of research protocols - closed session

❓ B00001265

❓ B00001274

Review of research amendments - closed session

? **B00000188-AM051**

? **B00000835-AM011**

? **B00001009-AM013**

Announcements

null

The meeting adjourned 4:00pm

- **Bio Protocol Number: B00001265**

PI Name: Vincent Ma

Protocol Title: UW26035, Kalivir Study, STEALTH-001

Motion: IBC approved with contingencies

Motion Made By: Joel Malak

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2;
Not applicable (non-laboratory area);

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood;
Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC),
Chemical fume hood; Not applicable; Biological safety cabinet (BSC), Chemical fume
hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents
involved in the proposed work. The IBC considered agent characteristics including but
not limited to pathogenicity, stability, and source and nature of recombinant and
synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used
effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required
institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved
in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative
controls deviate from the standards set by the IBC for the proposed materials and
activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the
NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing

information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-C-1);

Summary of IBC Review: This is a new protocol. This lab proposes to study the safety and efficacy of a genetically modified oncolytic vaccinia virus alone or with other immunotherapy treatments to participants with advanced solid tumors. The IBC discussed agent risks, attachments to the protocol, and occupational health plan guidance for UW Madison employees.

- **Bio Protocol Number: B00001274**

PI Name: Melanie Schmitt

Protocol Title: A Phase 1/2/3 Study of Subretinal AAV Gene Therapy [REDACTED] for RS1-Associated X-Linked Retinoschisis (LIGHTHOUSE)

Motion: IBC approved with contingencies

Motion Made By: Joel Malak

Motion Seconded By: Marta Gaglia

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees: Donna Neumann, abstain

Biosafety Level: BSL2; Not applicable (non-laboratory area);

Containment Equipment: Biological safety cabinet (BSC); Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines:

Summary of IBC Review: PI Status is approved. This is a new protocol. This lab proposes a clinical trial evaluating an investigational gene therapy to treat X-linked

retinoschisis that can cause vision loss in childhood. The IBC discussed contact for medical follow up for UW and clinical trial employees.

- **Bio Protocol Number: B00000188-AM051**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 051 for Genetic engineering of respiratory viruses

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Ryan Behrens

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees: Peter Halfmann, absent

Biosafety Level: BSL2; BSL2; ABSL2; ABSL2; BSL3+, ABSL3+; BSL-3Ag, ABSL-3Ag; ABSL-3Ag; BSL-3+, BSL-3Ag; ABSL2; ABSL1, ABSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2

Containment Equipment: Biological safety cabinet (BSC) and Chemical fume hood, Autoclave; Not applicable; Biological safety cabinet (BSC), Autoclave; Other, Filtered top cages; Biological safety cabinet (BSC), Autoclave; Biological safety cabinet (BSC), HEPA filtered downdraft table, HEPA filtered backdraft table; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Fume hood and BSCs

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-1-a)(III-D-1-b); (III-D-2-a); (III-D-3-a)(III-D-3-b)(III-D-3-e); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-a); (III-D-4-a)(III-D-4-b); III-D-7; (III-D-4-b); (III-

E-1); (III-E-1); (III-E-3); (III-F-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8)

Summary of IBC Review: Research in this laboratory focuses on select agent and non-select agent strains of influenza viruses, as well as various RG2 respiratory viruses. The select agent work has been approved by the Federal Select Agent Program. The IBC discussed biosafety level designation for microscopy rooms.

- **Bio Protocol Number: B00000835-AM011**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 011 for Pathogenesis of Staphylococcus aureus and Neisseria gonorrhoeae

Motion: IBC approved with contingencies

Motion Made By: Warren Rose

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Other - centrifuges, microscopes; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and/or laboratory staff must complete required institutional biosafety training. Final approval will be withheld until required biosafety training is complete.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a)

(III-D-1-b); (III-E); (III-E-1); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies pathogenesis of *Staphylococcus aureus* and *Neisseria gonorrhoeae*. In this amendment they propose to add work with *Listeria monocytogenes*. The IBC discussed the proposed changes and contingencies and had no additional concerns.

- **Bio Protocol Number: B00001009-AM013**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 013 for Molecular mechanisms that contribute to chronic pain

Motion: IBC approved with contingencies

Motion Made By: Yevgenya Grinblat

Motion Seconded By: Marta Gaglia

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL2; ABSL2; ABSL2; BSL1; BSL1; BSL1; BSL1; BSL1; BSL2; BSL1; ABSL2; ABSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and/or laboratory staff must complete required institutional biosafety training. Final approval will be withheld until required biosafety training is complete.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing

information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-3); (III-E-1); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This lab studies genetic mechanisms of chronic pain with the goal of identifying new drug targets. The amendment proposes to add a set of sodium channel modulators, which will be administered to cultured cells only. The IBC discussed BSL for human derived materials.

Other business -Closed session:

Stephanie Kutz gave the incident report.

Garret Suen gave the [REDACTED] lab quarterly update.

Christina Pier gave the DURC report.

A Motion was made regarding the WVDL protocol for an extension of one month to allow for additional discussion. Motion made by: Peter Halfmann; Seconded by: Sabine Pellett
Motion passed by: Hand vote, Opposed: Donna Neumann, No abstentions.